Related Experiment Videos
Summary
Aztreonam is a novel monobactam antimicrobial effective against aerobic gram-negative bacteria. Clinical trials show it is well-tolerated and effective for various infections, with potential for reduced resistance development.
Area of Science:
- Pharmacology
- Microbiology
- Clinical Medicine
Background:
- Aztreonam represents a new class of monobactam antimicrobials.
- It is nearing approval in the United States and Canada.
- Extensive in vitro and in vivo evaluations have been conducted.
Purpose of the Study:
- To review the chemistry, in vitro activity, pharmacokinetics, adverse reactions, and clinical use of aztreonam.
- To assess its potential role in antimicrobial therapy.
Main Methods:
- Review of existing data on aztreonam's properties and clinical applications.
- In vitro and in vivo studies evaluating its spectrum of activity and efficacy.
- Pharmacokinetic and adverse reaction profiling.
Main Results:
- Aztreonam exhibits a narrow spectrum, active against aerobic gram-negative microorganisms like Pseudomonas aeruginosa and resistant Enterobacteriaceae.
- It demonstrated high tissue concentrations, good tolerability, and efficacy comparable to gentamicin and cefamandole in treating serious urinary tract infections.
- Cure rates exceeded 85% in various infections, including gonococcal, lower respiratory tract, and intraabdominal infections.
- Elimination half-life is 1.6-2.2 hours in normal renal function, requiring dosage adjustment for renal impairment.
Conclusions:
- Aztreonam shows promise as an important antimicrobial agent with potential for lower resistance development compared to some cephalosporins.
- Further studies are necessary to fully assess its clinical efficacy, toxicity, and comparative advantages against other antibiotics.
- Its role in managing specific infections and impact on gut flora requires further investigation.